| 1 |
35135829 | Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements. | 2022 May 2 |
1 |
| 2 |
35400204 | Plain language summary of publication: new information for the potential role of afatinib in treating people with NRG1 gene fusion-positive cancer. | 2022 Jun |
5 |
| 3 |
32852072 | Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series. | 2021 Jan |
7 |
| 4 |
34805369 | Successful targeting of the NRG1 fusion reveals durable response to afatinib in lung adenocarcinoma: a case report. | 2021 Oct |
1 |
| 5 |
32916265 | NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents. | 2020 Dec |
2 |
| 6 |
31068372 | NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma. | 2019 Aug 1 |
4 |
| 7 |
30568455 | Afatinib reverses ceritinib resistance (CR) in ALK/ROS1-positive non-small-cell lung cancer cell (NSCLC) via suppression of NRG1 pathway. | 2018 |
5 |
| 8 |
28502724 | Durable Response to Afatinib in Lung Adenocarcinoma Harboring NRG1 Gene Fusions. | 2017 Aug |
1 |
| 9 |
29169524 | A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib. | 2017 Dec |
1 |